Splenectomy

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
0 Commercial trials
Drug classes (ATC)
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Vaccine 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • Medical University Of Vienna Academic
    RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE
    2023-508192-36-00 1 country 2024 n=80
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Medical University Of Vienna Academic 1 Phase II 0
New trials by year
2024
1
← All indication landscapes